ライフサイエンスコーパス: nalidixic

14 al distribution of the organism and apparent nalidixic acid (NAL) resistance.

15 ous Fenton-like reactions for the removal of nalidixic acid (NAL), a recalcitrant quinolone antibacte

16 The requirement for DksA in repair of nalidixic acid (Nal)-induced DSBs or for the formation o

17 susceptibility, the proportion resistant to nalidixic acid (NAL-R) increased from 2008 to 2012 (Typh

18 Typhi [MDRST]); 758 (38%) were resistant to nalidixic acid (nalidixic acid-resistant S. Typhi [NARST

19 The combination of neomycin-nalidixic acid (NNA) agar and a selective broth medium (

20 on blood agar medium containing neomycin and nalidixic acid (NNA).

21 were 2.2 [ampicillin (AMP), p=0.017] to 23 [nalidixic acid (NX), p<0.001] times more likely to harbo

22 ty of Todd-Hewitt medium with gentamicin and nalidixic acid (SBM) with our current method of direct p

23 0 microg of amphotericin B, and 20 microg of nalidixic acid (VAN) per ml.

24 occus isolates grown on blood agar, colistin-nalidixic acid agar (CNA), and mannitol salt agar (MSA);

25 B streptococcus, with culture using neomycin-nalidixic acid agar (NNA) and LIM broth.

26 eep blood agar, chocolate agar, and colistin-nalidixic acid agar after 24 to 48 h of incubation at 35

27 d sharply increasing trends in resistance to nalidixic acid and ciprofloxacin for both ST and SPA.

28 n it to be more sensitive to CCCP, PMA, PCP, nalidixic acid and DOC than the parent strain.

29 We identified two drugs, nalidixic acid and dorzolamide, that potently inhibit th

30 xacin), and three quinolones (oxolinic acid, nalidixic acid and flumequine) in eggs is presented.

31 e induced in a LexA-dependent manner by both nalidixic acid and mitomycin C, identifying these as mem

32 on and the addition of the gyrase inhibitors nalidixic acid and novobiocin.

33 emiselective blood agar medium incorporating nalidixic acid and sulfamethazine (NAS) is described.

34 ays a role in modulating the SOS response to nalidixic acid and that the response is more complex tha

35 ns known to be required for SOS induction by nalidixic acid are RecA and RecBC.

36 antially reduced for SOS induction following nalidixic acid but not UV treatment, and which were also

37 ot hydrolyze hippurate, and was sensitive to nalidixic acid but resistant to cephalothin.

38 Disk diffusion using these antibiotics and nalidixic acid failed to detect some low-level-resistant

39 els of the AcrAB-TolC pump, thereby removing nalidixic acid from the organism.

40 A subset of SOS genes lost their response to nalidixic acid in the dnaQ mutant strain, while two test

41 usceptible to ciprofloxacin but resistant to nalidixic acid in vitro, a pattern associated with fluor

42 Resistance to nalidixic acid may be useful in the identification of E.

43 howed increased survival on media containing nalidixic acid or rifampicin, but did not have an increa

44 ere uncovered as being uninducible by either nalidixic acid or UV treatment.

45 Nalidixic acid passed undegraded through the MBR and was

46 itt broth supplemented with 10 micrograms of nalidixic acid per ml and 15 micrograms of colistin per

47 The cellular response to nalidixic acid perturbation was analyzed using this form

48 s to rifampicin resistance (RifR) (rpoB) and nalidixic acid resistance (NalR) (gyrA).

49 es of spontaneous mutation to rifampicin and nalidixic acid resistance in one medium and one fast str

50 e efflux contributes to the overall level of nalidixic acid resistance.

51 d an identical pattern on PFGE, and all were nalidixic acid resistant.

52 e, such as qnr, is often not detected by the nalidixic acid screen test.

53 Quinolone antibacterial drugs such as nalidixic acid target DNA gyrase in Escherichia coli.

54 protect cells from the quinolone antibiotic nalidixic acid that induces a multidrug efflux pump and

55 perturb a GyrA-GyrA dimer interface allowed nalidixic acid to fragment chromosomes and kill cells in

56 A disk diffusion breakpoint was derived for nalidixic acid to serve as a surrogate marker for gyrase

57 Novobiocin and nalidixic acid treatment both resulted in rapid loss of

58 specifically deficient in SOS induction upon nalidixic acid treatment by using a dinD::lacZ reporter

59 of DNA fragments by GyrA antiserum following nalidixic acid treatment of cells.

60 chromosome replication was blocked by either nalidixic acid treatment or thymine starvation, the tran

61 hed greater than 10-fold in the medium after nalidixic acid treatment, suggesting these were released

62 ically necessary for SOS induction following nalidixic acid treatment.

63 several additional SOS genes in response to nalidixic acid using real-time PCR.

64 ween high efflux and increased resistance to nalidixic acid was found.

65 The deficient response to nalidixic acid was rescued by the presence of the wild-t

66 genes not previously known to be induced by nalidixic acid were also reproducibly upregulated.

67 duction and demonstrated that one quinolone (nalidixic acid) improved glucose tolerance in obese mice

68 rom the production of an antibacterial drug (nalidixic acid) was investigated employing a membrane bi

69 antibiotics (vancomycin, amphotericin B, and nalidixic acid), and the efficacy of solid (Herrold's eg

70 r characteristics, (ii) the concentration of nalidixic acid, (iii) the 48 organics identified in the

71 When nalidixic acid, a DNA synthesis inhibitor, was added to

72 on-inducible lexA mutant hypersusceptible to nalidixic acid, a property restricted to fluoroquinolone

73 azole, 312 (28%) to tetracycline, 19 (2%) to nalidixic acid, and 6 (0.5%) to ciprofloxacin.

74 In contrast, addition of rifampin, nalidixic acid, and chloramphenicol had little effect on

75 ant resistant to the prototype of quinolone, nalidixic acid, and created complexes on DNA detected by

76 eased spontaneous resistance to rifampin and nalidixic acid, and MMC/uvrD double mutants exhibited hi

77 g tetracycline, chloramphenicol, ampicillin, nalidixic acid, and rifampin.

78 ion elongation was blocked by hydroxyurea or nalidixic acid, arrested cells contained one partially r

79 DNA-damaging agents, such as mitomycin C and nalidixic acid, caused only limited elongation.

80 r alkaline phosphatase, and was resistant to nalidixic acid, cephalothin, and trimethoprim-sulfametho

81 , the MICs and inhibition zone diameters for nalidixic acid, ciprofloxacin, levofloxacin, and ofloxac

82 The prototype quinolone, nalidixic acid, kills wild-type Escherichia coli only by

83 cs, gentamicin, ceftazidime, nitrofurantoin, nalidixic acid, ofloxacin.

84 were selected on the basis of resistance to nalidixic acid, representing a variety of the most preva

85 eptibility to various antibiotics, including nalidixic acid, rifampin, novobiocin, and chloramphenico

86 re resistant to ampicillin, chloramphenicol, nalidixic acid, streptomycin, sulfisoxazole, tetracyclin

87 Nalidixic acid, the prototype antibacterial quinolone, i

88 bial mixture of polymyxin B, amphotericin B, nalidixic acid, trimethoprim, and azlocillin (PANTA) was

89 PANTA reagent (polymyxin B, amphotericin B, nalidixic acid, trimethoprim, and azlocillin), reconstit

90 oteins involved in the cytotoxic response to nalidixic acid, we screened for E. coli mutants specific

91 o the selection of the first clinical agent, nalidixic acid, were ever published by the discoverers.

92 he wild, stranded dolphins were sensitive to nalidixic acid, whereas the isolates from the collection

93 Overall, these results suggest that nalidixic acid-induced DNA breaks are generated either b

94 repair DNA damage via UV-induced DNA damage, nalidixic acid-induced double-strand breaks, and methyl

95 fraction of kanamycin-resistant (Km(r)) and nalidixic acid-resistant (Nal(r)) isolates showed reduce

96 About 10% of the nalidixic acid-resistant (Nal(r)) mutants in a transposi

97 ompared to 100% of those inoculated with the nalidixic acid-resistant (Nal(r)) parent and 100% of tho

98 triaxone was observed, 20 isolates (7%) were nalidixic acid-resistant (NARST).

99 ations in the gyrA gene were present in most nalidixic acid-resistant isolates.

100 758 (38%) were resistant to nalidixic acid (nalidixic acid-resistant S. Typhi [NARST]) and 734 NARST

101 We found a strong association between nalidixic acid-resistant Salmonella enterica serotype En

102 experiments, detection and enumeration of a nalidixic acid-resistant strain of E. coli O157 in bovin

103 Nalidixic acid-resistant strains harbored mutations in G

104 chloramphenicol, but all were susceptible to nalidixic acid.

105 and exhibited intermediate susceptibility to nalidixic acid.

106 ted for strongly by ciprofloxacin but not by nalidixic acid.

107 concentrations of rifampicin, kanamycin, and nalidixic acid.

108 m-sulfamethoxazole; 4 were also resistant to nalidixic acid.

109 pecifically deficient in the SOS response to nalidixic acid.

110 %) demonstrated a MIC > or = 16 microg/mL to nalidixic acid.

111 tment, and which were also hypersensitive to nalidixic acid.

112 om exogenous agents such as UV radiation and nalidixic acid.

113 ve and represent a more specific response to nalidixic acid.

114 e found to be upregulated in the presence of nalidixic acid.

115 lyze indoxyl acetate and their resistance to nalidixic acid.

116 ment of Health were tested for resistance to nalidixic acid.